Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications

Stem Cells. 1993 Nov;11(6):465-73. doi: 10.1002/stem.5530110616.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Review

MeSH terms

  • Anemia, Aplastic / classification
  • Anemia, Aplastic / therapy
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bone Marrow Diseases / blood
  • Bone Marrow Diseases / chemically induced
  • Bone Marrow Diseases / therapy*
  • Drug Therapy, Combination
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
  • Hematopoiesis / drug effects
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use*
  • Interleukin-3 / administration & dosage
  • Interleukin-3 / adverse effects
  • Interleukin-3 / therapeutic use*
  • Leukocyte Count / drug effects
  • Myelodysplastic Syndromes / blood
  • Myelodysplastic Syndromes / therapy
  • Neoplasms / complications
  • Neoplasms / drug therapy

Substances

  • Immunologic Factors
  • Interleukin-3
  • Granulocyte-Macrophage Colony-Stimulating Factor